Anika Therapeutics, Inc. held its Annual Meeting on June 20, 2025, where stockholders approved an amendment to increase shares under the 2017 Omnibus Incentive Plan by 475,000, now totaling 5,760,000 shares. Additionally, the meeting included voting on director nominees and approval of Deloitte & Touche LLP as the accounting firm for 2025.